Side-by-side comparison of AI visibility scores, market position, and capabilities
Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.
Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.5% to 13% testing 10K+ proteins for 30+ pharma/biotech partners competing with Recursion for AI drug discovery.
Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.